Xencor (NASDAQ:XNCR) Hits New 12-Month Low – Here’s What Happened

Xencor, Inc. (NASDAQ:XNCR) hit a new 52-week low during trading on Monday . The company traded as low as $15.14 and last traded at $15.16, with a volume of 89160 shares changing hands. The stock had previously closed at $15.74.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on XNCR shares. Wedbush reissued an “outperform” rating and set a $38.00 target price on shares of Xencor in a report on Thursday, November 7th. Wells Fargo & Company started coverage on shares of Xencor in a research note on Thursday, December 12th. They issued an “overweight” rating and a $37.00 price objective for the company. JPMorgan Chase & Co. raised their target price on shares of Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. BMO Capital Markets reiterated an “outperform” rating and issued a $34.00 price target (up from $32.00) on shares of Xencor in a research note on Friday, November 8th. Finally, Piper Sandler upgraded Xencor from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $20.00 to $30.00 in a research note on Monday, December 2nd. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Xencor has an average rating of “Buy” and an average price target of $34.88.

Xencor Trading Down 2.5 %

The firm’s 50-day simple moving average is $20.38 and its 200 day simple moving average is $20.74. The firm has a market capitalization of $1.07 billion, a price-to-earnings ratio of -4.79 and a beta of 0.70. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23.

Insider Buying and Selling

In other news, Director Alan Bruce Montgomery sold 1,421 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $27.03, for a total value of $38,409.63. Following the completion of the transaction, the director now directly owns 9,140 shares in the company, valued at approximately $247,054.20. This represents a 13.46 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.23% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Xencor

Several large investors have recently bought and sold shares of the company. Sterling Capital Management LLC increased its stake in shares of Xencor by 732.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,040 shares during the period. GF Fund Management CO. LTD. acquired a new position in Xencor in the 4th quarter valued at approximately $34,000. GAMMA Investing LLC raised its stake in shares of Xencor by 31.0% during the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 508 shares during the last quarter. KBC Group NV lifted its holdings in shares of Xencor by 63.5% during the third quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 1,213 shares during the period. Finally, Quarry LP grew its stake in shares of Xencor by 111.4% in the third quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock worth $80,000 after purchasing an additional 2,108 shares during the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.